Vaxdyn closes seed financial round with Bionova Capital with Connectem’s support

Mar 8, 2021 | Biotech, News

Vaxdyn closes seed financial round with Bionova Capital with Connectem’s support, to develop a new vaccine against deadly bacteria.

Vaxdyn, a Spanish biotech developing a novel vaccine to prevent deadly antibiotic-resistant bacterial infections has raised € 300,000 investment from Bionova Capital, a leading venture capital firm from Portugal.

Connectem Healthcare Business Consulting has fully supported Vaxdyn in all aspects of the fundraising process, including the final closing of this seed round.

The vaccine which is being developed by Vaxdyn will prevent infections caused by bacteria classified by the World Health Organization as the most dangerous for human health: Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Worryingly, no vaccines have been developed for these bacteria, and currently there are no candidates in clinical development.

Antibiotic-resistant bacteria could be the cause of the next pandemic as already more than 700,000 people die every year from antibiotic-resistant infections. If treatments against bacteria continue to be insufficient, 300 million people worldwide are expected to die prematurely from now until 2050, surpassing cancer as the main global killer.

From Connectem we are happy to support exciting Projects like Vaxdyn and help decrease the impact on public health of infections caused by drug-resistant pathogens.

About Vaxdyn

Vaxdyn is a biotech company dedicated to preventing life-threatening bacterial infections. Headquartered in Sevilla, Spain, Vaxdyn works with an international network of collaborators in the development of multi-valent vaccines for preventing infections in patients affected by chronic lung, liver or kidney diseases, immunocompromised patients with diabetes or cancer, and people under care at nursing homes and hospital settings.

About Bionova Capital

Bionova Capital based in Lisbon is a healthcare-focused venture capital firm, investing in early-stage life science companies. Founded in 2015, Bionova Capital actively manages a portfolio of six companies, two in the UK, one in Spain and three in Portugal. Bionova Capital invests in groundbreaking therapeutics, medtech and digital health startups across Europe.

About Connectem

Connectem is an international Business Consulting company in the fields of Pharma/Biotech, In Vitro Diagnostics, and medical devices. Connectem supports the Business Development and Fundraising processes of small to medium-sized Biotech companies,

Connectem is currently collaborating with Vaxdyn in its fundraising process, and will continue to support Vaxdyn in further financial rounds.